A Phase III, open label, randomized study of Atezolizumab (anti?PD-L1 antibody) compared with cisplatin or carboplatin ? pemetrexed for PD-L1?selected chemotherapy naive patients with stage IV non-squamous NSCLC (GO29431)
Supported projects > Other Supported Projects · 2017
Authors: Tuncay GÖKSEL
2017-2021, Other Supported Projects, R & D Project, Continues